2011-05-18T15:03:33-07:00 2010-06-30 990 2009-07-01 730580274 OKLAHOMA MEDICAL RESEARCH FOUNDATION OKLA 4052717421 825 NE 13th Oklahoma City OK 731045005 Tim Hassen 4052717421 2011-05-16 2009 2016-02-24 21:20:13Z Tim Hassen VP of Finance and CCFO 825 NE 13th street Oklahoma City OK 73104 77385304 0 X www.OMRF.org X 1946 OK OMRF is dedicated to developing a better understanding of and more effective treatments for human disease. 82 82 600 0 0 0 57281627 69877368 0 0 4019554 4095779 2845119 3022175 64146300 76995322 0 0 0 0 31924579 32395277 0 0 1540460 27811706 28754133 59736285 61149410 4410015 15845912 330893011 365771140 67562504 80149323 263330507 285621817 OMRF is dedicated to developing a better understanding of and more effective treatments for human disease. 0 0 15593737 0 13210743 Arthritis and Clinical Immunology This program focuses on autoimmune diseases, conditions in which the body turns its own immune system against itself. Already designated one of nine Autoimmunity Centers of Excellence in the U.S., OMRF in 2010 led the largest genetic experiment ever done in the field of lupus. Drs. Kathy Moser and Patrick Gaffney headed a team that analyzed massive amounts of data gathered from 15,000 blood samples donated by patients with lupus. Working with scientists from 33 institutions in Spain, Colombia, Canada, England, Sweden, Puerto Rico and the U.S., the scientists identified a genetic variant associated with lupus and, potentially, heart disease and certain kinds of cancer. Researchers in this program also spearheaded an effort that secured a National Institutes of Health construction grant to build out three floors of OMRF's new research tower. This, along with several other successful grant initiatives, was why OMRF ranked 4th among the 90 members of the Association of Independent Research Institutes for Recovery Act funding in 2010. 3424841 0 2492255 Immunobiology and Cancer A 2010 discovery by an OMRF immunobiologist could allow scientists to transform adult cells into stem cells. Using adult cells obtained from humans and mice, OMRF's Dr. Carol Webb reprogrammed the cells into a stem-cell-like condition. Once in this state, further research could allow scientists to transform the cells into more specialized cells, such as heart or nerve tissue. The finding offers promise that adult cells could be used as a plentiful and non-controversial alternative to embryonic stem cells. In the shorter term, the discovery could lead to a more efficient process for creating stem cells to treat people with leukemia. Over time, the work might also give rise to new therapies for spinal cord injuries, type I diabetes, heart disease and neurodegenerative conditions like Parkinson's and Lou Gehrig's diseases. 2010 also saw scientists in this program play a leading role in establishing the Oklahoma Center for Adult Stem Cell Research. Guided by OMRF's Dr. Paul Kincade, who was named the Center's founding scientific director, this initiative will provide support and resources for Oklahoma scientists seeking to develop a deeper understanding of and therapeutic uses for adult stem cells. 5255783 0 4703775 Cardiovascular Biology Sometimes, in an effort to fight off an infection, the body's immune system unleashes a response so massive that it causes life-threatening collateral damage. In a paper published in the journal Blood, Dr. Florea Lupu showed how an inhibitor administered at the right time can allow the immune system to go to work against infection and then shut off safely. The finding could play a part in stopping organ damage in patients suffering from trauma or the deadly blood poisoning sepsis. Dr. Hong Chen also made an important new finding-about the genetic roots of prostate cancer. The research could lead to new diagnostic tools to help physicians identify patients at greater risk for the deadly disease. The year closed with the American Heart Association honoring OMRF's Dr. Chuck Esmon with its 2010 Basic Research Prize. The AHA awarded the prize to Esmon for his "historic" contributions to researchers' understanding of the blood clotting system. Esmon's work, which includes identification of previously unrecognized proteins, led to the creation of two FDA-approved drugs: Xigris, for the treatment of severe sepsis, and Ceprotin, a therapeutic for patients suffering from a life-threatening protein deficiency. 32243792 0 8229566 All other Program Expenses including misc research and education 32243792 0 8229566 56518153 1 1 0 1 0 0 0 0 1 1 1 0 0 0 0 0 0 0 0 0 0 0 0 1 1 0 0 0 0 0 0 0 1 1 1 1 0 0 0 0 0 0 0 0 1 124 0 1 600 1 0 0 0 0 0 0 0 0 0 1 1 82 82 1 0 0 0 0 0 0 1 1 0 0 1 1 1 1 1 1 1 1 0 OK X X X Tim Hassen 4052717421 825 NE 13th St Oklahoma City OK 731045005 Allen Greg S 1 X 0 0 0 Anoatubby Bill 1 X 0 0 0 Bass James C 1 X 0 0 0 Bell Sharon J 1 X 0 0 0 Benbrook Bruce T 1 X 0 0 0 Benham Lance 1 X 0 0 0 Bialis Dave 1 X 0 0 0 Blankenship Elizabeth 1 X 0 0 0 Boghetich Jil 1 X 0 0 0 Braught Barbara M 1 X 0 0 0 Brown D Randolph 1 X 0 0 0 Burgess D Ellen 1 X 0 0 0 Burgess Bill Jr 1 X 0 0 0 Cameron Bill 1 X 0 0 0 Carolina C Michael 1 X 0 0 0 Carroll B Michael 1 X 0 0 0 Cason Len 1 X 0 0 0 Champlin Hiram H 1 X 0 0 0 Collins J Markham 1 X 0 0 0 Corbett Luke R 1 X 0 0 0 Cox Louis H 1 X 0 0 0 Crawford Bill 1 X 0 0 0 Drake Ramsey 1 X 0 0 0 Eagan Claire V 1 X 0 0 0 Edwards Carl 10 X 0 0 0 Evans Pat 1 X 0 0 0 Everest Christy 1 X 0 0 0 Felton Ann 1 X 0 0 0 Fergeson C Kendric 1 X 0 0 0 Ferree Larry D 1 X 0 0 0 Fischer Malinda Berry 1 X 0 0 0 Fretwell Barbara James 1 X 0 0 0 Funke Mark 1 X 0 0 0 Gamble Gerald L 1 X 0 0 0 Griffin John W 1 X 0 0 0 Griffin Martha 1 X 0 0 0 Groendyke Virginia 1 X 0 0 0 Haglund Jacqueline 1 X 0 0 0 Hall Brooks 1 X 0 0 0 Hamm Harold 1 X 0 0 0 Hargis V Burns 1 X 0 0 0 Hawley William 1 X 0 0 0 Healey Holly Cox 1 X 0 0 0 Henry Kim 1 X 0 0 0 Henry Robert H 1 X 0 0 0 Hogan Randy 1 X 0 0 0 Holmes Jerome 1 X 0 0 0 Hudson Cliff 1 X 0 0 0 Jameson Bretton 1 X 0 0 0 Keating Cathy 1 X 0 0 0 Kerr Lou 1 X 0 0 0 Levy Harrison 1 X 0 0 0 McCarty Jack De 1 X 0 0 0 McPherson Frank A 1 X 0 0 0 Mock Randall D 1 X 0 0 0 Morris Jim M 1 X 0 0 0 Mueller James A 1 X 0 0 0 Parry Richard H 1 X 0 0 0 Patten Rebecca J 1 X 0 0 0 Payne Jr Stephen B 1 X 0 0 0 Pierson Gary 1 X 0 0 0 Pitman Don W 1 X 0 0 0 Rainbolt David E 1 X 0 0 0 Rainbolt H E 1 X 0 0 0 Replogle Dee A 1 X 0 0 0 Robbins Galen 1 X 0 0 0 Rooney Patrick T 1 X 0 0 0 Ross Robert J 1 X 0 0 0 Samis Michael S 1 X 0 0 0 Saxon John H 1 X 0 0 0 Schulte Paul I 1 X 0 0 0 Stough Phyllis J 1 X 0 0 0 Swimmer Ross O 1 X 0 0 0 Swisher Bill 1 X 0 0 0 Switzer Becky 1 X 0 0 0 Taylor Kathryn L 1 X 0 0 0 Taylor Steven W 1 X 0 0 0 Thorpe Betsy Zahn 1 X 0 0 0 Walton Gregory F 1 X 0 0 0 Ward Lew 1 X 0 0 0 Williams Jr G Rainey 1 X 0 0 0 Wymer Deane 1 X 0 0 0 Prescott Stephen 50 X 825115 0 238739 Morgan Mike D 50 X 200385 0 7497 Cohen Adam 50 X 152549 0 6169 Kennedy Larry 50 X 144584 0 7363 Perrault Janis 50 X 127526 0 691 Hassen Tim 50 X 125851 0 11218 Voss Penny 50 X 125739 0 11118 Day Lisa 50 X 104482 0 5982 Harley John 50 X 464337 0 194121 JamesWood Judith 50 X 277707 0 17057 Kincade Paul W 50 X 210772 0 7497 Philip Silverman 50 X 186641 0 4289 Gaffney Patrick 50 X 186197 0 11353 Gorbsky Gary 50 X 185079 0 11350 Tang Jordan 50 X 178971 0 7460 Mcever Rodger P 50 X 290379 0 11396 Reichlin Morris 50 X 276554 0 7497 Capra Donald J 0 X 136000 0 0 4198868 0 560797 42 1 1 0 Perkins Will 1382 Peachtree St NE Atlanta GA 30309 Architect 1246813 Aramark 24863 Network Pl Chicago IL 606731248 House Keeping Services 483951 Fulbright Jaworski LLP 600 Congress Ave Ste 2400 Austin TX 78701 Legal 274223 Benham Companies LLC 9400 N Broadway STE 300 Oklahoma City OK 731147401 Consulting Construction 256205 Kilpatrick Stockton PO Box 945614 Atlanta GA 30394 Legal 202318 9 115496 0 0 0 54462467 15299405 37942 69877368 0 3643832 3643832 0 0 308860 308860 0 0 1426346 1426346 0 0 620620 0 0 0 620620 0 620620 620620 0 0 38806 494263 37926 352056 880 142207 143087 143087 0 0 0 Cafe Income 722100 220375 220375 0 0 Laboratory Income 541380 754834 754834 0 0 0 0 0 0 975209 76995322 7117954 0 0 0 0 0 0 0 0 0 0 2228445 1654162 451255 123028 0 0 0 0 22386164 20860611 733033 792520 0 0 0 0 7780668 7170259 300538 309871 0 0 0 0 0 0 0 0 712331 538044 174287 0 76720 57949 18771 0 308562 0 308562 0 0 0 0 0 0 0 1035571 1035571 0 0 0 0 0 0 627419 453700 60758 112961 612657 545848 15330 51479 0 0 0 0 2893320 2365799 526929 592 519822 465863 23459 30500 0 0 0 0 101594 94035 7519 40 494856 494856 0 0 0 0 0 0 6061329 5796843 264486 0 379635 286749 92886 0 Lab Supplies 6991968 6991968 0 0 Trainee Costs 1138752 1138752 0 0 Publications 189803 175160 3191 11452 Inhouse 1008213 958477 25697 24039 Subcontracts 4040845 4040845 0 0 1560736 1392662 84096 83978 61149410 56518153 3090797 1540460 5100 5700 59022379 75882612 16783110 12993040 2139450 1062987 0 0 0 0 104151 270074 7337 1916 458667 492862 163561741 69215793 72733886 94345948 75227711 74737244 866941 840644 0 0 0 103544279 105138113 330893011 365771140 9231404 10482355 0 0 0 0 55012035 66219273 0 0 0 0 0 0 0 0 3319065 3447695 67562504 80149323 X 71899931 89056088 42793820 45976179 148636756 150589550 263330507 285621817 330893011 365771140 X 0 1 1 X 1 1 X 47536878 56002982 77422808 57098803 69877368 307938839 0 0 0 0 0 0 0 0 0 0 0 0 47536878 56002982 77422808 57098803 69877368 307938839 0 307938839 7558719 7460788 17177534 6967812 7117954 46282807 0 0 0 0 0 0 0 0 0 0 0 0 354221646 0 0.86934 0.86215 X RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED 0 1 0 0 0 0 1 308562 0 0 308562 0 SchC_P2B_S00_L01 Schedule C, Part II-B, Line 1 The Foundation's lobbying acticities entail monitoring proposed legislation and educating legislators and their staffs about the Foundation, medical research and the impact of proposed legislation on medical research and the Foundation. 58951820 239636 2975964 0 3300000 0 58867420 73407691 1652223 -12908094 0 3200000 0 58951820 0.03 0.2 0.77 1 0 3944520 0 3944520 94392359 0 49355970 45036389 0 0 0 0 30133670 0 19859823 10273847 35091192 0 0 35091192 94345948 0 840644 C 840644 Funds Held in Trust by Others 101879803 Wills & Bequests, Net 1915466 Debt Issuance Costs 742005 Cash Surrender Value of Life Insurance Polcies 297276 Deposits 141992 Accrued Interest Receivable 112504 Inventory - Land and Building 48970 Minerals 97 105138113 Split Interest Agreements & Other Liabilities 661501 Postretirement Benefits & Deferred Compensation 2786194 3447695 76995322 61149410 15845912 6224424 0 0 0 220974 6445398 22291310 76995322 0 0 0 0 0 76995322 0 0 0 76995322 61149410 0 0 0 0 0 61149410 0 0 0 61149410 SchD_P05_S00_L04 Schedule D, Part V, Line 4 The Foundation's endowment consists of individual funds established to provide the Foundation with funding in perpetuity. SchD_P10_S00_L00 Schedule D, Part X Not applicable. SchD_P11_S00_L08 Schedule D, Part XI, Line 8 Pension related changes other than net periodic pension cost. X 1 1 X X X X X X 0 1 0 0 0 0 0 1 0 Prescott Stephen 625040 0 175000 0 25075 0 227068 0 7455 0 1059638 0 1125655 0 Morgan Mike D 175310 0 0 0 25075 0 0 0 7497 0 207882 0 202622 0 Cohen Adam 150492 0 0 0 2057 0 0 0 6169 0 158718 0 141849 0 Kennedy Larry 140931 0 0 0 3653 0 0 0 7363 0 151947 0 149499 0 Perrault Janis 125450 0 0 0 2076 0 0 0 11224 0 138750 0 135296 0 Hassen Tim 124349 0 0 0 1503 0 0 0 11218 0 137070 0 133744 0 Voss Penny 109629 0 0 0 16110 0 0 0 11118 0 136857 0 134299 0 Day Lisa 102880 0 0 0 1602 0 0 0 5982 0 110464 0 104960 0 Harley John 269969 0 0 0 1068 0 193300 0 821 0 465158 0 375319 JamesWood Judith 260583 0 0 0 17124 0 10779 0 6278 0 294764 0 305642 0 Mcever Rodger P 265305 0 0 0 25075 0 0 0 11396 0 301776 0 303095 0 Reichlin Morris 268166 0 0 0 8388 0 0 0 7497 0 284051 0 256071 0 Kincade Paul W 186159 0 0 0 24613 0 0 0 7497 0 218269 0 213077 0 Philip Silverman 163975 0 0 0 22666 0 0 0 4289 0 190930 0 0 0 Gaffney Patrick 175775 0 0 0 10423 0 0 0 11353 0 197551 0 197196 0 Gorbsky Gary 166339 0 0 0 18741 0 0 0 11350 0 196430 0 189698 0 Tang Jordan 175383 0 0 0 3588 0 0 0 7460 0 186431 0 0 0 SchJ_P01_S00_L01a Schedule J, Part I, Line 1a Fisrt class travel is allowed for the CEO to allow him to accomplish work related tasks while traveling. SchJ_P01_S00_L03 Schedule J, Part I, Line 3 Compensation for the CEO is determined by leadership of the board of directors based on comaparbility data from widely accepted peer benchmarking salary surveys that are segmented by region and size of entity. SchJ_P01_S00_L04 Schedule J, Part I, Line 4 The Board of the Foundation periodically uses nonqualified retirement plans as a retention tool. SchJ_P01_S00_L07 Schedule J, Part I, Line 7 The CEO receives an annual bonus that is determined by leadership of the board of directors based on performance. The bonus is considered as a portion of total compensation and is subject to the review process previously described. Oklahoma Industries Authority 736194355 679103YC9 2008-08-14 42955000 Revenue Bonds (OMRF Project) series 2008 0 0 Oklahoma Industries Authority 736194355 XXNONEXXX 2010-05-26 12185000 Revenue Bonds (OMRF Project) series 2010 0 0 43457720 3316750 0 30342872 141976 0 9652617 2011 0 0 0 1 12320300 96501 12137699 0 138825 0 0 2011 0 1 0 1 0 0 0 1 1 0 0 0 1 0 0 0 1 1 0 0 0 1 0 0 0 0 0 0 0 0 0 0 0 0 Benham Companies Common Directors 242000 Construction Managment 0 Capra Consulting >35% owned by Former Officer 136000 Management Consulting 0 Bank of Oklahoma Common Directors 96000 Investment and mineral asset management 0 Bank Of Oklahoma Common Directors 61000 Bond Underwriting 0 Peter Carl Related to Board member 49150 Payroll 0 X 16 880 FMV 0 0 1 0 F990_P06_S0A_L02 Form 990, Part VI, Section A, Line 2 The Foundation currently has 82 directors, many of whom are business leaders and members of prominent families in the State of Oklahoma. The Foundation believes there are multiple business relationships between and among board members and families of board members, but the Foundation review of signed conflict of interest disclosures from all board members and of the Foundation's ledger accounts indicated there are no such relationships that would impair the fiduciary duties of any director to the Foundation. F990_P06_S0B_L11 Form 990, Part VI, Section B, Line 11 A summary of the Form 990 is presented for review to the Executive Committee. Subsequent to that review, the Form 990 and all supplemental schedules is made available to all members of the board of directors for review and comment prior to filing. F990_P06_S0B_L12c Form 990, Part VI, Section B, Line 12c Each director, officer and key employee is annually provided with a copy of the Foundation's conflict of interest policy. Each of these individuals is annually provided with a questionnaire regarding potential conflicts and required to disclose any potential conflict that he or she might have. In addition, each of these individuals must annually sign a statement affirming that he or she has; received a copy of the conflicts of interest polciy, read and understood the policy and agrees to comply with the policy. Once the Foundation has collected annual disclosure statements from all directors, officers and key employees, the Foundation's Governance Committee reviews such information to identify situations in which a conflict exists and is material. If a material conflict is identified, the Committee analyzes whether the contemplated transcation may be authorized as just, fair, and reasonable to the Foundation. The Governance Committee then makes a recommendations to the Foundation's Executive Committee regarding the management of all potential conflicts it has identified. The final decision as to the approval and, where applicable, management of all such potential conflicts rests in the sole discretion of the Executive Committee, which makes such decisions based upon the welfare of the Foundation and the advancement of its purpose. The recommendations of the Governance Committee and decisions of the Executive Committee are documented in the respective minutes of these Committees' regular meetings. F990_P06_S0B_L15 Form 990, Part VI, Section B, Line 15 Compensation for Officers is determined and evaluated annually by leadership of the board of directors based on comparability data from widely accepted peer benchmarking salary surveys that are segmented by regieon and size of entity. Compensation for principal investigators (lead researchers), including any key employees, is determined by Foundation Officers based on the comparability data referenced above. The last salary evaluation for these individuals was conducted between June and October of 2008. F990_P06_S0C_L19 Form 990, Part VI, Section C, Line 19 The Foundation's governing documents, conflicts of interest policy, and financial statements are provided upon request and are publicily available on the Foundation's website. The person responsible for filing the 990 had a family emergency and was unable to file May 16th. It was May 18th before the oversight was identified.